Product-Specific Guidance for Semaglutide: FDA Requirements for Generic Drug Development
Product-Specific Guidance for Semaglutide: FDA Requirements for Generic Drug Development Read More »
What Is the Difference Between PLGA and PLGA-PEG for Nanoparticle Drug Delivery?
Introduction: PLGA vs PLGA-PEG for nanoparticle drug delivery is one of the first formulation decisions a sponsor faces when designing
What Is the Difference Between PLGA and PLGA-PEG for Nanoparticle Drug Delivery? Read More »
Biosimilar Functional Bioassay Development Service: Cell-Based and Binding Assays for Regulatory Dossiers
Introduction A specialized Biosimilar Functional Bioassay Development Service provides Mechanism of Action (MoA)-reflective cell-based and binding assays that are specifically
Purification Techniques for Peptide-Oligonucleotide Conjugates (HPLC, Ion Exchange, SEC)
Introduction The optimization of Purification Techniques for Peptide-Oligonucleotide Conjugates depends on the strategic application of orthogonal chromatographic methodologies capable of
Purification Techniques for Peptide-Oligonucleotide Conjugates (HPLC, Ion Exchange, SEC) Read More »
Drug Substance vs Drug Product CDMO: Understanding the Split and When to Use Each
Introduction The decision to adopt a consolidated or split Drug Substance vs Drug Product CDMO model plays a pivotal role
Drug Substance vs Drug Product CDMO: Understanding the Split and When to Use Each Read More »
Peptide Characterization CRO Services for IND Submission: What the Full Analytical Data Package Looks Like
Introduction A comprehensive analytical data package prepared for an Investigational New Drug (IND) submission provides regulatory agencies with robust structural,
How Do Peptide-Oligonucleotide Conjugates Enter Cells? Internalization Pathways Explained
Introduction Peptide-oligonucleotide conjugates gain entry into cells mainly through energy-dependent endocytosis or energy-independent direct plasma membrane translocation, with the dominant
One-Stop CDMO Analytical Services for ANDA: Method Development, Validation, and CMC Documentation
Introduction Obtaining approval for an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) requires manufacturers
Peptide Characterization Services for Biosimilar and Complex Drug Applications
Introduction: Peptide Characterization Services play a critical role in the successful development of biosimilars and complex peptide therapeutics. Regulatory agencies
Peptide Characterization Services for Biosimilar and Complex Drug Applications Read More »
